首页  >  学科前沿 {{articleInfo.dynamicName}}  > 国际TOP10医学期刊药物治疗信息 (2024年1月)

国际TOP10医学期刊药物治疗信息 (2024年1月)

{{releTime.slice(0,10)}}     来源:药物治疗网     编辑:艾玉娇     阅读量:7271

一、临床肿瘤杂志 (2024年第74卷第1期)

January/February 2024 - Volume 74 - Issue 1 (2024年1/2月第74卷第1期)
https://acsjournals.onlinelibrary.wiley.com/toc/15424863/2024/74/1

二、柳叶刀 (2024年第403卷第10421-10424期)

(一)06 January 2024 - Volume 403 - Issue 10421 (2024年1月6日第403卷第10421期)
https://www.thelancet.com/journals/lancet/issue/vol403no10421/PIIS0140-6736(23)X0053-1

ARTICLES(文章)
1. 阿替利珠单抗联合贝伐珠单抗和化疗治疗转移性、持续性或复发性宫颈癌(BEATcc):一项随机、开放标签的3期试验
(Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial)
作者:Ana Oaknin* (Medical Oncology Service, Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Spain)

(二)13 January 2024 - Volume 403 - Issue 10422 (2024年1月13日第403卷第10422期)
https://www.thelancet.com/journals/lancet/issue/vol403no10422/PIIS0140-6736(24)X0002-1

COMMENT(评论)
1. ligelizumab与奥马珠单抗治疗慢性自发性荨麻疹的疗效比较
(Comparative efficacy of ligelizumab versus omalizumab in chronic spontaneous urticaria)
作者:Sarah Moussa, Elena Netchiporouk* (Faculty of Medicine, McGill University, Canada; Division of Dermatology, Department of Medicine, McGill University, QC, CanadaMcGill University Health Centre, Canada)
2. 毒蕈碱药物对精神分裂症有疗效,但仍有问题尚待发掘
(Muscarinic drug shows efficacy in schizophrenia but much is left to be discovered)作者:Andrea Cipriani* (Department of Psychiatry, University of Oxford, Oxford OX3 7JX, UKOxford Precision Psychiatry Lab, NIHR Oxford Health Biomedical Research Centre, Oxford, UKOxford Health NHS Foundation Trust, Warneford Hospital, UK)
3. 将霍乱疫苗推到流行曲线之前
(Moving cholera vaccines ahead of the epidemic curve)
作者:Ziad A Memish* (Research and Innovation Center, King Saud Medical City, Ministry of Health, Riyadh 11553, Saudi ArabiaCollege of Medicine, Alfaisal University, Saudi ArabiaKyung Hee University, Seoul, South KoreaHubert Department of Global Health, Rollins School of Public Health, Emory University, USA)
4. 可转让的独家代金券:刺激抗生素创新但有缺陷的激励措施
(Transferable exclusivity voucher: a flawed incentive to stimulate antibiotic innovation)
作者:Christine Årdal* (Antimicrobial Resistance Centre, Norwegian Institute of Public Health, Norway)

ARTICLES(文章)
5. ligelizumab治疗成人和青少年慢性自发性荨麻疹的疗效和安全性:两项3期随机对照试验的结果
(Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials)
作者:Marcus Maurer* (Urticaria Center of Reference and Excellence (UCARE), Institute of Allergology, Germany)
6. 在美国,毒蕈碱受体激动剂KarXT(xanomeline-trospium)治疗精神分裂症(EMERGENT-2)的疗效和安全性:一项随机、双盲、安慰剂对照、灵活剂量的3期试验的结果
(Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial)
作者:Inder Kaul, Steven M Paul* (Karuna Therapeutics, USA)

(三)20 January 2024 - Volume 403 - Issue 10423 (2024年1月20日第403卷第10423期)
https://www.thelancet.com/journals/lancet/issue/vol403no10423/PIIS0140-6736(24)X0003-3

ARTICLES(文章)
1. Imetelstat在复发或对红细胞生成刺激剂难治的低危骨髓增生异常综合征患者中的应用(IMerge):一项多国、随机、双盲、安慰剂对照的3期试验
(Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial)
作者:Uwe Platzbecker* (Department of Hematology, Cellular Therapy, Infectious Diseases, and Hemostaseology, University Hospital Leipzig, Germany)
2. 减少benralizumab(SHAMAL)治疗的严重嗜酸性粒细胞性哮喘患者的每日维持吸入性皮质类固醇用量:一项随机、多中心、开放标签的4期研究
(Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study)
作者:David J Jackson* (School of Immunology & Microbial Sciences, Guy's Hospital, King's College London, UK)

(四)27 January 2024 - Volume 403 - Issue 10424 (2024年1月27日第403卷第10424期)
https://www.thelancet.com/journals/lancet/issue/vol403no10424/PIIS0140-6736(24)X0004-5

COMMENT(评论)
1. 双氢青蒿素-哌喹用于HIV感染孕妇的疟疾预防
(Dihydroartemisinin–piperaquine for prevention of malaria in pregnant women living with HIV)
作者:Moses R Kamya* (Department of Medicine, Makerere University, PO Box 7072, Kampala, UgandaInfectious Diseases Research Collaboration, Uganda)
2. 阻断醛固酮或其受体——有什么区别?
(Blocking aldosterone or its receptor—what is the difference?)
作者:Rajiv Agarwal* (Richard L Roudebush VA Medical Center, Indianapolis, IN, USAIndiana University School of Medicine, USA)

ARTICLES(文章)
3. 在肯尼亚和马拉维,对感染HIV的孕妇每日服用复方新诺明,每月使用双氢青蒿素-哌喹间歇性预防治疗疟疾:一项随机、双盲、安慰剂对照试验
(Chemoprevention for malaria with monthly intermittent preventive treatment with dihydroartemisinin–piperaquine in pregnant women living with HIV on daily co-trimoxazole in Kenya and Malawi: a randomised, double-blind, placebo-controlled trial)
作者:Hellen C Barsosio* (Kenya Medical Research Institute, Centre for Global Health Research, Kenya)
4. 是否使用恩格列净抑制醛固酮合成酶抑制治疗慢性肾病的疗效和安全性醛固酮合酶抑制是否联合恩格列净在治疗慢性肾脏病方面的疗效和安全性:一项随机、对照、2期试验
(Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial)
作者:Katherine R Tuttle* (Providence Inland Northwest Health, USA)

三、新英格兰医学杂志 (2024年1月第390卷第1-4期)

(一)4 January 2024 - Volume 390 - No 1 (2024年1月4日第390卷第1期)

https://www.nejm.org/toc/nejm/390/1

ORIGINAL ARTICLES(原创文章)
1. 药物洗脱可吸收支架与血管成形术治疗腘下动脉疾病的比较
(Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease)
作者:Ramon L. Varcoe1, Brian G. DeRubertis2, Sahil A. Parikh3* (1.Prince of Wales Hospital and University of New South Wales, Australia; 2. New York Presbyterian–Weill Cornell Medical Center ,USA; 3.Columbia University Irving Medical Center, USA)
2. Sibeprenlimab治疗IgA肾病患者的2期试验
(A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy)
作者:Mohit Mathur* (Visterra, USA)
3. 超声血脑屏障开放和Aducanumab治疗阿尔茨海默病
(Ultrasound Blood–Brain Barrier Opening and Aducanumab in Alzheimer’s Disease)
作者:Ali R. Rezai* (Rockefeller Neuroscience Institute, West Virginia University, USA)

CORRESPONDENCE(通信)
4. 恩杂鲁胺在生化复发性前列腺癌中的应用
(Enzalutamide in Biochemically Recurrent Prostate Cancer)
5. 艾氯胺酮鼻喷雾剂与喹硫平治疗顽固性抑郁症的比较
(Esketamine Nasal Spray versus Quetiapine for Resistant Depression)

(二)11 January 2024 - Volume 390 - No 2 (2024年1月11日第390卷第2期)
https://www.nejm.org/toc/nejm/390/2

ORIGINAL ARTICLES(原创文章)
1. 阿哌沙班用于亚临床心房颤动的卒中预防
(Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation)
作者:Jeff S. Healey* (Population Health Research Institute, McMaster University, Canada)
2. 瑞普替尼治疗ROS1融合阳性非小细胞肺癌
(Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer)
作者:Alexander Drilon*, Byoung Chul Cho* (Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, USA; Yonsei University College of Medicine, South Korea)
3. Acoramidis治疗转甲状腺素蛋白淀粉样心肌病的疗效和安全性
(Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy)
作者:Julian D. Gillmore* (National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital, UK)

CORRESPONDENCE(通信)
4. 妊娠期合并1型糖尿病期间的自动胰岛素输送
(Automated Insulin Delivery during Pregnancy Complicated by Type 1 Diabetes)

(三)18 January 2024 - Volume 390 - No 3 (2024年1月18日第390卷第3期)
https://www.nejm.org/toc/nejm/390/3

ORIGINAL ARTICLES(原创文章)
1. 男性性腺功能减退症的睾酮治疗和骨折
(Testosterone Treatment and Fractures in Men with Hypogonadism)
作者:Susan S. Ellenberg1, Jane A. Cauley2, Kevin A. Buhr3, Peter J. Snyder1* (1. Perelman School of Medicine, University of Pennsylvania, USA; 2. University of Pittsburgh Graduate School of Public Health, USA; 3. University of Wisconsin Statistical Data Analysis Center, USA)
2. 在婴儿健康常规访视期间阿奇霉素可预防死亡
(Azithromycin during Routine Well-Infant Visits to Prevent Death)
作者:Thomas M. Lietman, Catherine E. Oldenburg* (Department of Ophthalmology, and the Institute for Global Health Sciences, USA)
3. 口服Simnotrelvir治疗轻至中度Covid-19成人患者
(Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19)
作者:Bin Cao1*, Yeming Wang1, Hongzhou Lu2, Chaolin Huang3, Yumei Yang4 (1. Departments of Pulmonary and Critical Care Medicine, China; 2. Department of Infectious Diseases, Third People’s Hospital of Shenzhen, National Clinical Research Center for Infectious Diseases, China; 3. Jin Yin-tan Hospital, China; 4. Department of Medicine, Non-oncology, Jiangsu Simcere Pharmaceutical, China)

EDITORIAL(社论)
4. 突发新闻—老年男性的睾丸治疗和骨折
(Breaking News — Testosterone Treatment and Fractures in Older Men)
作者:Mathis Grossmann (University of Melbourne, Melbourne, and the Department of Endocrinology, Austin Health, Australia)

CORRESPONDENCE(通信)
5. Patisiran 治疗转甲状腺素蛋白心肌淀粉样变性患者
(Patisiran in Patients with Transthyretin Cardiac Amyloidosis)
6. 度伐利尤单抗用于可切除的非小细胞肺癌的围手术期治疗
(Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer)
7. 关于司美格鲁肽治疗早期1型糖尿病的更多信息
(More on Semaglutide in Early Type 1 Diabetes)

(四)25 January 2024 - Volume 390 - No 4 (2024年1月25日第390卷第4期)
https://www.nejm.org/toc/nejm/390/4

ORIGINAL ARTICLES(原创文章)
1. 达雷妥尤单抗、硼替佐米、来那度胺和地塞米松治疗多发性骨髓瘤
(Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma)
作者:Pieter Sonneveld* (Erasmus MC Cancer Institute, the Netherlands)
2. 布洛芬选择性早期治疗动脉导管未闭的试验
(Trial of Selective Early Treatment of Patent Ductus Arteriosus with Ibuprofen)
作者:Pollyanna Hardy1, Edmund Juszczak2, Samir Gupta3* (1. National Perinatal Epidemiology Unit Clinical Trials Unit, Nuffield Department of Population Health, University of Oxford, UK; 2. School of Medicine, University of Nottingham, UK; 3. Division of Neonatology, Sidra Medicine, UK)

CORRESPONDENCE(通信)
3. Alpelisib辅助治疗先天性高胰岛素血症
(Adjuvant Alpelisib Therapy for Congenital Hyperinsulinism)
4. 塞普替尼或化疗治疗RET融合阳性非小细胞肺癌
(Selpercatinib or Chemotherapy in RET Fusion–Positive NSCLC)
5. 地塞米松治疗HIV阳性成人结核性脑膜炎
(Dexamethasone for Tuberculous Meningitis in HIV-Positive Adults)
6. 肉毒毒素治疗孤立性或原发性头部震颤
(Botulinum Toxin for Isolated or Essential Head Tremor)

CORRECTION(校正)
7. 阿伐可泮 用于治疗ANCA相关血管炎
(Avacopan for the Treatment of ANCA-Associated Vasculitis)
【注】ANCA:抗中性粒细胞胞浆抗体(Anti-neutrophil cytoplasmic antibodies)
8. 阿伐可泮—是时候取代糖皮质激素了吗?
(Avacopan — Time to Replace Glucocorticoids?)

四、美国医学会杂志 (2024年1月第331卷第1-4期)

(一)2 January 2024 -Volume 331 - No.1 (2024年1月2日第331卷第1期)
https://jamanetwork.com/journals/jama/issue/331/1

Original Investigation(原始调查)
1.替尔泊肽持续治疗成人肥胖症维持体重减轻 SURMOUNT-4 随机临床试验
(Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity The SURMOUNT-4 Randomized Clinical Trial)
作者:Louis J. Aronne (Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, USA)

Medical News & Perspectives(医学新闻与亮点)
2.在 ObesityWeek上发表了关于司美格鲁肽、替尔泊肽和Retatrutide的更多数据和问题
(At ObesityWeek, More Data and Questions About Semaglutide, Tirzepatide, and Retatrutide)
作者:Kate Ruder

Medical News in Brief(医学新闻简讯)
3.许多符合条件的患者未使用他汀类药物进行一级预防
(Many Eligible Patients Do Not Use Statins for Primary Prevention)
作者:Emily Harris

(二)9 January 2024 -Volume 331 - No.2 (2024年1月9日第331卷第2期)
https://jamanetwork.com/journals/jama/issue/331/2

Research Letter(研究信)
1. 使用单一雌激素治疗女性痴呆
(Dementia in Women Using Estrogen-Only Therapy)
作者:Nelsan Pourhadi (Danish Dementia Research Centre, Copenhagen University Hospital–Rigshospitalet, Denmark)

Viewpoint(观点)
2. 可能限制Zuranolone效用的担忧
(Concerns That May Limit the Utility of Zuranolone)
作者:Vinay Prasad (University of California San Francisco, USA)

Medical News & Perspectives(医学新闻和观点)
3. 研究调查Paxlovid等抗病毒药物是否可以预防长期COVID
(Studies Investigate Whether Antivirals Like Paxlovid May Prevent Long COVID)
作者:Melissa Suran

(三)16 January 2024 -Volume 331 - No.3 (2024年1月16日第331卷第3期)
https://jamanetwork.com/journals/jama/issue/331/3

Original Investigation(原始调查)
1. 可切除的非小细胞肺癌患者围手术期使用托利单抗联合化疗 Neotorch随机临床试验
(Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer The Neotorch Randomized Clinical Trial)
作者:Shun Lu (Department of Medical Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, China)

JAMA Insights(JAMA见解)
2. 纳洛酮滴鼻治疗阿片类药物过量
(Intranasal Naloxone for Opioid Overdose)
作者:Jessica L. Taylor (Grayken Center for Addiction, Boston Medical Center, USA)

JAMA Patient Page(JAMA 患者页面)
3. 成人过敏性鼻炎的非处方治疗
(Nonprescription Medications for Adults With Allergic Rhinitis)
作者:Sarah E. Vordenberg (Clinical Pharmacy, University of Michigan College of Pharmacy, USA)

Comment & Response(评论与回应)
4. 阿莫西林-克拉维酸与阿莫西林治疗小儿急性鼻窦炎的比较
(Amoxicillin-Clavulanate vs Amoxicillin for Pediatric Acute Sinusitis)
作者:Na He (Department of Pharmacy, Peking University Third Hospital, China)
5. 阿莫西林-克拉维酸与阿莫西林治疗小儿急性鼻窦炎的比较—回复
(Amoxicillin-Clavulanate vs Amoxicillin for Pediatric Acute Sinusitis—Reply)
作者:Timothy J. Savage (Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, USA)

(四)23/30 January 2024 -Volume 331 - No.4 (2024年1月23/30日第331卷第4期)
https://jamanetwork.com/journals/jama/currentissue

Medical News in Brief(医学新闻简讯)
1. 停止服用二线糖尿病药物的患者数量“令人担忧
(“Alarming” Number of Patients Stop Taking Second-Line Diabetes Drugs)
作者:Emily Harris
2. 妊娠期GLP-1受体激动剂的首次大型研究
(First Large Study of GLP-1 Receptor Agonists During Pregnancy)
作者:Emily Harris
3. 大剂量流感疫苗可能对中年人更有效
(High-Dose Flu Vaccine May Be More Effective for Midlife Adults)
作者:Emily Harris

五、自然:药物发现综述

January 2024 - Volume 23 - Issue 1 (2024年1月第23卷第1期)
https://www.nature.com/nrd/volumes/23/issues/1

NEWS IN BRIEF(简讯)
1. FDA批准第一种基孔肯雅热疫苗
(FDA approves first chikungunya vaccine)
作者:Asher Mullard
2. FDA批准同类首个AKT抑制剂
(FDA approves first-in-class AKT inhibitor)
作者:Asher Mullard
3. γ分泌酶抑制剂首次获得批准
(γ-secretase inhibitor notches first approval)
作者:Katie Kingwell

RESEARCH HIGHLIGHT(研究亮点)
4. PROTAC在自身免疫性皮肤病中的临床应用
(PROTAC in clinic for autoimmune skin disease)
作者:Alex Eccleston
5. 抗革兰阴性病原体的抗体
(Antibodies combat Gram-negative pathogen)
作者:Sarah Crunkhorn
6. 抗体实现瘦素平衡
(Antibodies achieve leptin balancing act)
作者:M. Teresa Villanueva
7. 一种更安全的多烯类抗真菌药
(A safer polyene antifungal)
作者:Sarah Crunkhorn

Review Article(评论文章)
8. NLRP3炎症小体的药物治疗:从信号机制到治疗靶点
(Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets)
作者:Lieselotte Vande Walle, Mohamed Lamkanfi* (Laboratory of Medical Immunology, Department of Internal Medicine and Paediatrics, Ghent University, Belgium)

六、自然:免疫学综述 (2024年1月第24卷第1期)

January 2024 - Volume 24 - Issue 1 (2024年1月第24卷第1期)
https://www.nature.com/nri/volumes/24/issues/1

Research Highlight(研究亮点)
1. 通过抑制肾上腺素受体促进淋巴引流,保护受损的大脑
(Boosting glymphatic drainage via adrenergic receptor inhibition protects the injured brain)
作者:Yvonne Bordon

七、柳叶刀:呼吸医学 (2024年第12卷第1期)

January 2024 - Volume 12 - Number 1 (2024年第12卷第1期)
https://www.thelancet.com/journals/lanres/issue/vol12no1/PIIS2213-2600(23)X0013-7

COMMENT(社论)
1. 每天服用一次他克莫司可减少肺移植慢性排斥反应
(Once-per-day tacrolimus to reduce chronic lung transplant rejection)
作者:Michael P Combs* (Division of Pulmonary & Critical Care, University of Michigan, USA)
2. 度普利尤单抗:引导进一步研究的发现之旅
(Dupilumab: VOYAGE of discovery leading to a further EXCURSION)
作者:Emmanouil Paraskakis* (Paediatric Respiratory Unit, Paediatric Department, University Hospital of Heraklion, University of Crete, Greece)

ARTICLES(文章)
3. 上皮钠通道阻滞剂idrevloride 在原发性纤毛运动障碍患者中的安全性和有效性(CLEAN-PCD):一项多国、随机、双盲、安慰剂对照的2 期交叉试验
(Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): a multinational, phase 2, randomised, double-blind, placebo-controlled crossover trial)
作者:Felix C Ringshausen* (Department of Respiratory Medicine and Infectious Diseases, German Center for Lung Research and European Reference Network for Rare and Complex Lung Diseases, Hannover Medical School, Germany)
4. 在斯堪的纳维亚每日一次他克莫司与每日两次环孢素对肺移植术后3年慢性同种异体肺功能障碍发生率的影响(ScanCLAD):一项多中心随机对照试验
(Effect of once-per-day tacrolimus versus twice-per-day ciclosporin on 3-year incidence of chronic lung allograft dysfunction after lung transplantation in Scandinavia (ScanCLAD): a multicentre randomised controlled trial)
作者:Göran Dellgren* (Transplant Institute and Department of Cardiothoracic Surgery, Sahlgrenska University Hospital, University of Gothenburg, Sweden)
5. 度普利尤单抗在哮喘患儿中的长期安全性和有效性评估(LIBERTY ASTHMA EXCURSION):一项开放标签的扩展研究
(Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study)
作者:Leonard B Bacharier* (Division of Allergy, Immunology and Pulmonary Medicine, Monroe Carell Jr. Children's Hospital at Vanderbilt University Medical Center, USA)
6. 英国初级保健中血液嗜酸性粒细胞引导的口服强的松龙治疗COPD急性发作(STARR2):一项非劣效性、多中心、双盲、安慰剂对照、随机对照试验
(Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care in the UK (STARR2): a non-inferiority, multicentre, double-blind, placebo-controlled, randomised controlled trial)
作者:Sanjay Ramakrishnan, Mona Bafadhel* (Respiratory Medicine Unit, Nuffield Department of Clinical Medicine, University of Oxford, UK; King's Centre for Lung Health, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, UK)

八、英国医学期刊 (2024年1月第384卷第8412-8414期)

(一)13 January 2024 - Volume 38 - Issue 8412 (2024年1月13日第384卷第8412期)
https://www.bmj.com/content/384/8412

本期无药学相关内容

(二)20 January 2024 - Volume 384 - Issue 8413(2024年1月20日第384卷第8413期)
https://www.bmj.com/content/384/8413

News(新闻)
1. 研究警告称加巴喷丁类药物可导致慢性阻塞性肺病患者严重恶化
(Gabapentinoids can cause severe exacerbation in patients with COPD, research warns)
作者:Elisabeth Mahase

Letters(信件)
2. 司美格鲁肽可将主要心血管事件的绝对风险降低1.5%
(Semaglutide reduces the absolute risk of major cardiovascular events by 1.5%)
作者:David Phizackerley (Drug and Therapeutics Bulletin, UK)
3. 质子泵抑制剂的眼科副作用
(Ophthalmological side effects of proton pump inhibitors)
作者:Gianni Zuccheri

Practice(实践)
4. Vitamin B12
(维生素B12)
作者:Bruce HR Wolffenbuttel* (University of Groningen, University Medical Center Groningen, Netherlands)

(三)27 January 2024 - Volume 384 - Issue 8414 (2024年1月27日第384卷第8414期)
https://www.bmj.com/content/384/8414

News(新闻)
1. 丙戊酸钠:监管机构表示,计划生育的男性应根据儿童的神经发育障碍风险寻求建议
(Valproate: Men planning a family should seek advice in light of neurodevelopmental disorders risk in children, says regulator)
作者:Jacqui Wise
2. 英国监管机构表示,氟喹诺酮类抗生素仅作为最后手段开具
(Fluoroquinolone antibiotics: Prescribe only as last resort, says UK regulator)
作者:Gareth Iacobucci

Practice(实践)
3. 氨甲环酸治疗急性出血的疗效和安全性
(Efficacy and safety of tranexamic acid in acute haemorrhage)
作者:Massimo Franchini* (Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Italy)

九、自然:医学 (2024年1月第30卷第1期)

January 2024 - Volume 30 - Issue 1 (2024年1月第30卷第1期)
https://www.nature.com/nm/volumes/30/issues/1

Correspondence(通讯)
1. 俄勒冈州支持裸盖菇素使用的安全性
(The safety of supported psilocybin use in Oregon)
作者:William R. Smith* (Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, USA)

Comment(评论)
2. GLP-1受体激动剂治疗肥胖症的供给不平等
(Inequalities in the provision of GLP-1 receptor agonists for the treatment of obesity)
作者:Stephanie W. Waldrop*, Veronica R. Johnson (University of Colorado School of Medicine–Anschutz Medical Campus, Department of Pediatrics, Section on Nutrition and Lifestyle Medicine, Nutrition Obesity Research Center at the University of Colorado (CUNORC), USA; Northwestern University Feinberg School of Medicine, Department of Medicine, Division of General Internal Medicine, USA)

研究简报(Research Briefing)
3. 司美格鲁肽与自杀意念风险的关系
(Semaglutide and risk of suicidal ideations)

Article(文章)
4. 奈玛特韦/利托那韦在感染SARS-CoV-2奥密克戎孕妇中的应用:靶向试验模拟
(Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation)
作者:Carlos K. H. Wong1*, Kristy T. K. Lau2, Matthew S. H. Chung2, Ivan C. H. Au2 (Laboratory of Data Discovery for Health (D24H), Hong Kong SAR, China; Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China)
5. 一种预防疟疾的候选抗体药物
(A candidate antibody drug for prevention of malaria)
作者:Katherine L. Williams* (Atreca, Inc., USA)
6. 抗疟药物青蒿琥酯-甲氟喹与吡喹酮治疗非洲儿童血吸虫病的比较:一项开放标签、随机对照试验
(Antimalarial artesunate–mefloquine versus praziquantel in African children with schistosomiasis: an open-label, randomized controlled trial)
作者:Emmanuel Bottieau*, Moustapha Mbow (Department of Clinical Sciences, Institute of Tropical Medicine, Belgium; Institute for Health Research, Epidemiological Surveillance and Training (IRESSEF), Senegal)
7. 真实世界队列中司美格鲁肽与自杀意念风险的关联
(Association of semaglutide with risk of suicidal ideation in a real-world cohort)
作者:William Wang, Nora D. Volkow* (Center for Science, Health, and Society, Case Western Reserve University School of Medicine, USA; National Institute on Drug Abuse, National Institutes of Health, USA)
8. bidridistrogene xebparvovec基因疗法治疗2E/R4型肢带型肌营养不良:1/2期试验结果(Gene therapy with bidridistrogene xeboparvovec for limb-girdle muscular dystrophy type 2E/R4: phase 1/2 trial results)
作者:Jerry R. Mendell, Louise R. Rodino-Klapac* (Center for Gene Therapy, The Research Institute at Nationwide Children’s Hospital, USA; Sarepta Therapeutics, Inc., USA)
9. II型RAF抑制剂tovorafenib治疗复发/难治性小儿低级别胶质瘤:2期FIREFLY-1试验
(The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial)
作者:Lindsay B. Kilburn* (Children’s National Hospital, USA)
10. 莫妥珠单抗联合polatuzumab vedotin治疗复发或难治性侵袭性大B细胞淋巴瘤:一项1b/2期试验
(Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial)
作者:Lihua E. Budde* (City of Hope Comprehensive Cancer Center, USA)
11. 替雷利珠单抗联合泽布替尼治疗Richter转化:2期RT1试验
(Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial)
作者:Othman Al-Sawaf* (Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Germany)
12. 特瑞普利单抗联合白蛋白结合型紫杉醇治疗转移性或复发性三阴性乳腺癌:一项随机3期试验
(Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial)
作者:Zefei Jiang1*, Quchang Ouyang2, Tao Sun3, Qingyuan Zhang4 (1. Fifth Medical Center of Chinese PLA General Hospital, China; 2. Breast Internal Medicine Department, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, China; 3. Breast Medicine Ward Area I, Liaoning Cancer Hospital, China; 4. Department of Breast & Lymphoma, Harbin Medical University Cancer Hospital, China)
13. 他拉唑帕利联合恩扎卢胺一线治疗HRR缺陷转移性去势抵抗性前列腺癌:3期TALAPRO-2试验
(First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial)
作者:Karim Fizazi*, Neeraj Agarwal* (Institut Gustave Roussy, University of Paris-Saclay, France; Huntsman Cancer Institute (NCI-CCC), University of Utah, USA)
14. Sotorasib联合帕尼单抗治疗化疗难治性KRASG12C-突变结直肠癌:1b期试验
(Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial)
作者:Yasutoshi Kuboki1, Marwan Fakih2, John Strickler3, Rona Yaeger4, David S. Hong5* (1. National Cancer Center Hospital East, Japan; 2. City of Hope Comprehensive Cancer Center, USA; 3. Duke University Medical Center, USA; 4. Memorial Sloan Kettering Cancer Center, USA; 5. The University of Texas MD Anderson Cancer Center, USA)
15. Divarasib联合西妥昔单抗治疗KRAS G12C阳性结直肠癌:一项1b期试验
(Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial)
作者:Jayesh Desai* (Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Australia)

Author Correction(作者更正)
16. 作者更正:Vorasidenib和艾伏尼布治疗IDH1突变型低级别胶质瘤:一项随机、围手术期1期试验
(Author Correction: Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial)
作者: Ingo K. Mellinghoff*, Min Lu (Memorial Sloan Kettering Cancer Center, USA; Mersana Therapeutics, USA)
17. 作者更正:阿替利珠单抗治疗可切除非小细胞肺癌的新辅助治疗:一项开放标签、单臂II期试验
(Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial)
作者:Jamie E. Chaft (Memorial Sloan Kettering Cancer Center, USA)
18. 作者更正:靶向Tau反义寡核苷酸MAPTRx治疗轻度阿尔茨海默病:一项1b期、随机、安慰剂对照试验
(Author Correction: Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial)
作者:Catherine J. Mummery* (Dementia Research Centre, National Hospital for Neurology and Neurosurgery, University College London, UK)
19. 作者更正:III期尿路上皮癌术前采用大剂量或小剂量伊匹木单抗联合纳武利尤单抗治疗:1B期NABUCCO试验
(Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial)
作者: Jeroen van Dorp1, Christodoulos Pipinikas2, Greg Jones2*, Michiel S. van der Heijden3* (1. Department of Molecular Carcinogenesis, Netherlands Cancer Institute, The Netherlands; 2. Inivata Ltd., Babraham Research Park, UK, 3. Dutch Uro-Oncology Study Group, The Netherlands)

十、世界精神病学 (2024年第23卷第1期)

(一)2024 - Volume 23 - Issue 1 (2024年第23卷第1期)
https://onlinelibrary.wiley.com/toc/20515545/2024/23/1

Insight(见解)
1.在用精神药物治疗女性时,需要考虑性别差异
(Sex differences need to be considered when treating women with psychotropic drugs)
作者:Iris E. Sommer (Department of Psychiatry, University Medical Center Groningen, The Netherlands)

Letter to the Editor(致编辑的信)
2.抑郁症序贯治疗后的累积缓解率:STAR*D试验数据的再评价
(Cumulative remission rate after sequential treatments in depression: reappraisal of the STAR*D trial data)
作者:Hitoshi Sakurai (Department of Neuropsychiatry, Kyorin University Faculty of Medicine, Japan)
3.当与迷幻药联用时,心理治疗应如何进行?
(How should psychotherapy proceed when adjoined with psychedelics?)
作者:Marc J. Weintraub (Department of Psychiatry and Biobehavioral Sciences, University of California, and Semel Institute for Neuroscience and Behavior, USA)

网友评论